Press Releases

    • SEP 11 2017

    Oncoceutics Begins ONC201 Endometrial Cancer Trial; Receives NIH Grant

    Philadelphia, PA (September 11, 2017) – Oncoceutics, Inc. announced the launch of a clinical trial of ONC201 for patients with recurrent or metastatic endometrial cancer at the Fox Chase Cancer Center. The Phase II trial, being led by Gina Mantia-Smaldone, MD, Assistant Professor in the Department of Surgical Oncology, is listed on under NCT03099499

    • AUG 11 2017

    ONC201 Trial for Neuroendocrine Cancer Begins at Cleveland Clinic

    Philadelphia, PA (Aug 9, 2017) – Oncoceutics, Inc. announced today that the first patient has been treated in a Phase II clinical trial of ONC201 for patients with recurrent or metastatic neuroendocrine tumors at the Cleveland Clinic. The selection of neuroendocrine tumors for a clinical trial was driven by the discovery in 2016 that ONC201

    • JUL 10 2017

    Mechanistic Study Uncovers New Utility of ONC201 Mechanism in Lymphoma

    Philadelphia, PA (July 10, 2017) – Oncoceutics, Inc. announced the publication of a scientific manuscript from collaborators at the University of Texas MD Anderson Cancer Center (MDACC) that describes ONC201’s ability to control a set of anti-cancer signaling pathways to induce cell death in tumor, but not  normal cells. The publication, from the laboratory of

    • JUN 28 2017

    Oncoceutics Extends Patent Family to Include ONC201 in Leukemias

    Philadelphia, PA (June 28, 2017) – Oncoceutics, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued patent #9,688,679 for the use of ONC201 to treat all leukemias, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). ONC201, a member of the imipridone family, has demonstrated anti-cancer activity and safety in preclinical